Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00538720 · ClinicalTrials.gov registry record · Phase 1

Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)

A Phase 1 study of Hyperparathyroidism, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT00538720 is a Phase 1 study of Hyperparathyroidism that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants, below the 131-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00538720, a Phase 1 study of Hyperparathyroidism, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn how the standard practice of giving Vitamin D supplements to patients with a Vitamin D deficiency may affect the size of the parathyroid glands in patients with PHPT and a Vitamin D deficiency.

Conditions Studied

Interventions

  • DRUG Vitamin D
  • DEVICE Four-dimensional computed tomography (4DCT)

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2007-10
Est. Completion 2018-05-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00538720

The ClinicalTrials.gov registry entry for NCT00538720 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (83% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Vitamin D is the first listed.

NCT00538720 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00538720 about?

NCT00538720 is a clinical study titled "Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)". The goal of this clinical research study is to learn how the standard practice of giving Vitamin D supplements to patients with a Vitamin D deficiency may affect the size of the parathyroid glands in patients with PHPT and a Vitamin D deficiency.

What is the current status of trial NCT00538720?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-10. Estimated completion is 2018-05-30.

What conditions does trial NCT00538720 study?

This clinical trial studies the following conditions: Hyperparathyroidism.

What interventions are being tested in trial NCT00538720?

The interventions under investigation include: Vitamin D (DRUG), Four-dimensional computed tomography (4DCT) (DEVICE).

Who is sponsoring clinical trial NCT00538720?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00538720 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.